Cagrilintide
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Novo Nordisk |
| Mechanism | Long-acting amylin receptor agonist |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~11.5% at 68 weeks (REDEFINE 1 monotherapy) |
| Status | Phase 3 — commercialized as half of CagriSema |
Deep dive
What Is Cagrilintide? The Amylin Analog Behind CagriSema →Novo Nordisk's long-acting amylin analog — 11.5% weight loss as monotherapy, and the key ingredient in CagriSema.
Cagrilintide compared
Every head-to-head we've published involving Cagrilintide.
Comparison
Retatrutide vs CagriSema (Cagrilintide + Semaglutide): Triple Agonist vs Amylin + GLP-1 Combo
Cagrilintide vs retatrutide: triple agonist vs amylin + GLP-1 combo — 28.7% vs 22.7% weight loss, different receptors, and stacking considerations.
Updated February 2026
Comparison
Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist
Cagrilintide + tirzepatide stacking: no human trial data, CagriSema lost to tirzepatide in REDEFINE 4, and retatrutide offers 28.7% weight loss from one molecule.
Updated February 2026
Related articles
Safety, mechanism, and context pieces that reference Cagrilintide.
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.